These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38247190)

  • 1. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
    Chupradit S; Wamalwa DC; Maleche-Obimbo E; Kekitiinwa AR; Mwanga-Amumpaire J; Bukusi EA; Nyandiko WM; Mbuthia JK; Swanson A; ; Cressey TR; Punyawudho B; Musiime V;
    Clin Pharmacol Ther; 2024 May; 115(5):1105-1113. PubMed ID: 38247190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
    Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.
    Chaivichacharn P; Avihingsanon A; Gatechompol S; Ubolyam S; Punyawudho B
    Drug Metab Pharmacokinet; 2022 Dec; 47():100478. PubMed ID: 36375225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe.
    Pasipanodya B; Kuwengwa R; Prust ML; Stewart B; Chakanyuka C; Murimwa T; Brophy J; Salami O; Mushavi A; Apollo T
    J Int AIDS Soc; 2018 Dec; 21(12):e25214. PubMed ID: 30549217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
    Wang K; D'Argenio DZ; Acosta EP; Sheth AN; Delille C; Lennox JL; Kerstner-Wood C; Ofotokun I
    Clin Pharmacokinet; 2014 Apr; 53(4):361-71. PubMed ID: 24311282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
    Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
    Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
    Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV.
    Niu WJ; Sun T; Liu L; Liu XQ; Zhang RF; Yin L; Wang JR; Jia XF; Lu HZ; Zhong MK; Jiao Z; Zhang LJ
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):456-465. PubMed ID: 30346663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
    Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV
    J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
    Owor M; Tierney C; Ziemba L; Browning R; Moye J; Graham B; Reding C; Costello D; Norman J; Wiesner L; Hughes E; Whalen ME; Purdue L; Mmbaga BT; Kamthunzi P; Kawalazira R; Nathoo K; Bradford S; Coletti A; Aweeka F; Musoke P
    Pediatr Infect Dis J; 2021 May; 40(5):446-452. PubMed ID: 33464021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
    Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2094-101. PubMed ID: 25624326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.
    Patterson KB; Dumond JB; Prince HA; Jenkins AJ; Scarsi KK; Wang R; Malone S; Hudgens MG; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 May; 63(1):51-8. PubMed ID: 23221983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.